Despite promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant resistance from pharmacy benefit managers. The insurers are https://nanniehyrn700189.worldblogged.com/48420700/copyright-s-vyndamax-faces-is-dealing-with-pharmacy-benefit-manager-obstacles-the-review-at-reimbursement-battles